Cost-effectiveness analysis of OM-85 vs placebo in the prevention of acute respiratory tract infections (ARTIs) in children that attend day-care centers

Health Economics Review

Volumn 9, Issue 1, 2019, Pages

  Berber, Arturo ^a   Del Rio Navarro, Blanca Estela ^b  

^a Fundación Para El Avance de la Ciencia   (Mexico)

^b HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

Author keywords

Acute respiratory tract infection; Day care center; Immunostimulant; OM 85; Prevention

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BACTERIUM LYSATE; CEFALEXIN; CEFUROXIME; CEPHALOSPORIN; CLARITHROMYCIN; IBUPROFEN; NIMESULIDE; PARACETAMOL; PLACEBO;

ARTICLE; BOOTSTRAPPING; CHILD; COST EFFECTIVENESS ANALYSIS; DAY CARE; DECISION MAKING; DECISION TREE; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SYSTEMATIC REVIEW;

EID: 85065484562     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/s13561-019-0230-1     Document Type: Article

References (23)

1. Ochoa Sangrador C, Barajas Sánchez MV, Muñoz Martín B. Relationship between child day-care attendance and acute infectious disease. A systematic review. Rev Esp Salud Publica. 2007;81:113-29.
2. Flores-Hernandez S, Reyes-Morales H, Perez-Cuevas R, et al. The day care center as a risk factor for acute respiratory infections. Arch Med Res. 1999;30:216-23.
3. Enserink R, Lugnér A, Suijkerbuijk A, et al. Gastrointestinal and respiratory illness in children that do and do not attend child day care centers: a cost-of-illness study. PLoS One 2014;9(8):e104940. doi: https://doi.org/10.1371/journal.pone.0104940. eCollection 2014.
4. Delpiano L, Kabalán P, Díaz C, et al. Características y costos directos de infecciones respiratorias agudas en niños de guarderías infantiles [acute respiratory infections in children of day care center: characteristics and costs]. Rev Chil Infect. 2006;23(2):128-33.
5. Ahrens J. Multicentre double-blind clinical trial with broncho-vaxom in children. Therapiewoche. 1984;34:3469-75.
6. Collet JP, Ducruet T, Kramer MS, et al. Stimulation of nonspecific immunity to reduce the risk of recurrent infections in children attending day-care centers. The Epicreche Research Group Pediatr Infect Dis J. 1993;12:648-52.
7. Del Río Navarro BE, Sienra Monge JJL, Berber A, et al. Use of OM-85 BV in children suffering from recurrent respiratory tract infections and subnormal IgG subclass levels. Allergol Immunopathol (Madr). 2003;31:7-13.
8. Gomez Barreto D, De la Torre C, Alvarez A, et al. Safety and efficacy of OM-85-BV plus amoxicillin/clavulanate in the treatment of subacute sinusitis and the prevention of recurrent infections in children [Seguridad y eficacia de OM-85-BV más amoxicilina/clavulanato en el tratamiento de la sinusitis subaguda y prevención de infecciones recurrentes en niños]. Allergol Immunopathol (Madr). 1998;26:17-22.
9. Gutiérrez-Tarango MD, Berber A. Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months. Chest. 2001;119:1742-8.
10. Jara-Perez JV, Berber A. Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial. Clin Ther. 2000;22:748-59.
11. Maestroni GJ, Losa GA. Clinical and immunobiological effects of an orally administered bacterial extract. Int J Immunopharmacol. 1984;6:111-7.
12. Martin du Pan RE, Martin du Pan RC. Clinical study concerning the prevention of infections of the upper respiratory tract of preschool children. Schweiz Rundsch Med Prax. 1982;71:1385-9.
13. Paupe J. Immunotherapy with an oral bacterial extract (OM-85 BV) for upper respiratory infections. Respiration. 1991;58:150-4.
14. Schaad UB, Farine JC, Fux T. Prospective placebo-controlled double-blind study using a bacterial lysate in infections of the respiratory tract and ENT region in children [prospective placebo-kontrollierte Doppelblindstudie mit einem Bakterienlysat bei Infektionen der Atemwege und des ORL-Bereiches im Kindesalter]. Helv Paediatr Acta. 1986;41:7-17.
15. Schaad UB, Mutterlein R, Goffin H, et al. Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a doubleblind, placebo-controlled multicenter study. Chest. 2002;122:2042-9.
16. Zagar S, Lofler-Badzek D. Broncho-vaxom in children with rhinosinusitis: a double-blind clinical trial. ORL J Otorhinolaryngol Relat Spec. 1988;50:397-404.
17. Del-Rio-Navarro BE, Espinosa-Rosales FJ, Flenady V, Sienra-Monge JJ. Cochrane review: Immunostimulants for preventing respiratory tract infection in children. Evidence-Based Child Health: A Cochrane Review Journal. 2012;7:629-717.
18. De-la-Torre-Gonzalez C, Pacheco-Rios A, Escalante-Dominguez AJ, et al. Comparative metaanalysis of immunostimulant agents used in pediatric patients in Mexico [Metaanalisis comparativo de los inmunoestimulantes utilizados enpediatría en México]. Rev Alerg Mex. 2005;52:25-38.
19. Del-Rio-Navarro BE, Espinosa-Rosales FJ, Flenady V, et al. Immunostimulants for preventing respiratory tract infection in children. Cochrane Database Syst Rev. Issue 4. Art. No.: CD004974. DOI: https://doi.org/10.1002/14651858.CD004974.pub2.
20. Pessey JJ, Migas F, Arnould B, et al. Prevention of recurrent rhinopharyngitis in at-risk children in France: a cost-effectiveness model for a nonspecific immunostimulating bacterial extract (OM-85 BV). Pharmacoeconomics. 2003;21:1053-68.
21. Zaniolo O, Pradelli L, Eandi M. OM-85, cost/effectiveness, upper respiratory tract infections (URTIs) [Costo/efficacia della prevenzione di infezioni alle prime vie aeree mediante un estratto batterico immunostimolante aspecifico (OM-85)] Farmeconomia e percorsi terapeutici. 2005; 6 (3): 169-184.
22. Ravasio R. Economic analysis of the Immunostimulant OM-85 for the prevention of Paediatric recurrent upper respiratory tract infections. Glob Regional Health Technol Assess. 2015;2(3):135-42.
23. Field J, Gomez-Barreto D, Del-Rio-Navarro BE, et al. Use of OM-85 BV in primary prevention of acute respiratory tract infections in children in orphanages. Curr Ther Res Clin Exp. 1998;59:407-18.